The Antifolates - 20/04/12
Corresponding author. Departments of Medicines, Molecular Pharmacology and the Albert Einstein Cancer Center, The Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461.Résumé |
This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics. New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.
Le texte complet de cet article est disponible en PDF.Keywords : Methotrexate, Pralatrexate, Pemetrexed, Antifolates, Reduced folate carrier (RFC), Proton-coupled folate transporter (PCFT), Folate receptors, Folate receptor-mediated endocytosis
Plan
Vol 26 - N° 3
P. 629-648 - juin 2012 Retour au numéro
Article précédent
- Antimitotic Inhibitors
- Susana M. Campos, Don S. Dizon
- Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment
- Sook Ryun Park, Alice Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?